Tislelizumab 100mg/10ml solution for infusion vials
Prescription only
Requires a prescription from a doctor or prescriber
Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1).
Active ingredients:
Tislelizumab
1 safety notice
Safety information for pregnancy and breastfeeding
Pregnancy
There are no available data on the use of tislelizumab in pregnant women.
Based on its mechanism of action, tislelizumab can cause fetal harm when administered to a pregnant woman.[L49349]
Animal reproduction studies have not been conducted with tislelizumab.
Animal reproduction studies have not been conducted with tislelizumab.
However, in murine models of pregnancy, blockade of PD-1/PD-L1 signaling has been shown to disrupt tolerance to the fetus and result in increased fetal loss.[L49349]
Human IgG4 (immunoglobulins) are known to cross the placental barrier.
Human IgG4 (immunoglobulins) are known to cross the placental barrier.
Therefore, tislelizumab, being an IgG4 variant, has the potential to be transmitted from the mother to the developing fetus.[L49349]
Women should be advised of the potential risk to a fetus.
Women should be advised of the potential risk to a fetus.
Tislelizumab should not be used during pregnancy unless the clinical condition of the woman requires treatment with tislelizumab.[L49349]
No clinical data are available on the possible effects of tislelizumab on fertility.
No clinical data are available on the possible effects of tislelizumab on fertility.
Always consult your doctor or midwife before taking any medicine during pregnancy or while breastfeeding. Source: DrugBank (CC BY-NC 4.0).
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
MHRA
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Tislelizumab
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
EMA
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Tislelizumab
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
1 products
MHRA licensed products
View all licensed products for Tislelizumab on the MHRA register
Possibly available on the UK market
Tevimbra 100mg/10ml concentrate for solution for infusion vials
Therapeutically similar medicines
Serplulimab 100mg/10ml solution for infusion vials
Infusion
100mg/10ml
Same therapeutic group
Nivolumab 600mg/5ml solution for injection vials
Injection
600mg/5ml
Same therapeutic group
Pembrolizumab 80mg/50ml in Sodium chloride 0.9% infusion bags
Infusion
80mg/50ml
Same therapeutic group
Pembrolizumab 225mg/100ml in Sodium chloride 0.9% infusion bags
Infusion
225mg/100ml
Same therapeutic group
Pembrolizumab 100mg/50ml in Sodium chloride 0.9% infusion bags
Infusion
100mg/50ml
Same therapeutic group
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Loading prescribing data...
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Searching UK clinical trials...
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
23.8 days
Mechanism
Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cel…
Food interactions
None known
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
0.5 to 10 mg/k
The pharmacokinetics (PK) of tislelizumab were characterized using population PK analysis with concentration data from 2 596 patients with advanced malignancies who received tislelizumab doses of 0.5…
Half-life
23.8 days
Based on population PK analysis, the geometrical mean terminal half-life of tislelizumab was approximately 23.8…
Protein binding
Little information is available on the protein binding of tislelizumab.
Volume of distribution
6.42 L
A population pharmacokinetic analysis indicates that the steady-state volume of distribution is 6.42…
Metabolism
Tislelizumab is expected to be degraded into small peptides and amino acids via catabolic pathways.
[L49349]
[L49349]
Clearance
0.153 l
Based on population PK analysis, the clearance of tislelizumab was 0.153 l/day with an interindividual variability of 26.3%.
[L49349]
[L49349]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Status:
Approved
Investigational
Biologic
About this compound
Tislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis.[A262909] By blocking PD-L1/PD-L2–mediated cell signaling, tislelizumab restores T-cell function through cytokine production, resulting in immune-mediated antitumor responses.[A262919] Tislelizumab is generally well tolerated with manageable and mild-to-moderate adverse effects.[A262924]
On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA. This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy.[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349]
On September 25, 2023, tislelizumab gained EMA approval as a monotherapy for adults with esophageal cancer under the brand name TEVIMBRA. This approval was based on positive results demonstrated in the RATIONALE 302 study, where an 8.6-month median overall survival rate was observed for tislelizumab treatment compared to 6.3-month for chemotherapy.[L49439] Tislelizumab was also approved by the FDA on March 14, 2024.[L50346] It has subsequently been approved for additional cancers in the US and EU. [L49349]
Properties:
liquid
DrugBank indication
Esophageal Squamous Cell Carcinoma (ESCC)
Tislelizumab, in combination with platinum-containing chemotherapy, is indicated as a first-line treatment in adults with unresectable or metastatic ESCC whose tumors express PD-L1.
[L52310]
Tislelizumab, as a monotherapy, is indicated for the treatment of adults with:
- Unresectable ESCC [L49349][L52310]
- Locally advanced ESCC [L49349]
- Metastatic ESCC following prior systemic chemotherapy that did not include a PD-(L)1 inhibitor, such as platinum-based chemotherapy.
[L49349][L52310]
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Tislelizumab, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumors express PD-L1.
[L52310]
Extensive-Stage Small Cell Lung Cancer
In the EU, tislelizumab is indicated in combination with [etoposide] and platinum chemotherapy for the first-line treatment of adult patients with extensive-stage SCLC.
[L49349]
Non-Small Cell Lung Cancer (NSCLC)
In the EU, tislelizumab is approved as a monotherapy for adults with locally advanced or metastatic NSCLC after prior platinum-based therapy. For patients with EGFR mutant or ALK-positive NSCLC, targeted therapies should have been received prior to tislelizumab.
[L49349]
Non-Squamous NSCLC
In combination with [pemetrexed] and platinum-containing chemotherapy, tislelizumab is indicated for the first-line treatment of adults with non-squamous NSCLC whose tumors:
- Have PD-L1 expression on ≥50% of tumor cells
- Have no EGFR or ALK-positive mutations and who have either: Locally advanced NSCLC not eligible for surgical resection or platinum-based chemoradiation, or Metastatic NSCLC.
[L49349]
Squamous NSCLC
In combination with [carboplatin] and either [paclitaxel] or nab-paclitaxel, tislelizumab is indicated for the first-line treatment of adults with squamous NSCLC who have either: Locally advanced NSCLC not eligible for surgical resection or platinum-based chemoradiation, or Metastatic NSCLC.
[L49349]
Tislelizumab, in combination with platinum-containing chemotherapy, is indicated as a first-line treatment in adults with unresectable or metastatic ESCC whose tumors express PD-L1.
[L52310]
Tislelizumab, as a monotherapy, is indicated for the treatment of adults with:
- Unresectable ESCC [L49349][L52310]
- Locally advanced ESCC [L49349]
- Metastatic ESCC following prior systemic chemotherapy that did not include a PD-(L)1 inhibitor, such as platinum-based chemotherapy.
[L49349][L52310]
Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Tislelizumab, in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic HER2-negative gastric or GEJ adenocarcinoma whose tumors express PD-L1.
[L52310]
Extensive-Stage Small Cell Lung Cancer
In the EU, tislelizumab is indicated in combination with [etoposide] and platinum chemotherapy for the first-line treatment of adult patients with extensive-stage SCLC.
[L49349]
Non-Small Cell Lung Cancer (NSCLC)
In the EU, tislelizumab is approved as a monotherapy for adults with locally advanced or metastatic NSCLC after prior platinum-based therapy. For patients with EGFR mutant or ALK-positive NSCLC, targeted therapies should have been received prior to tislelizumab.
[L49349]
Non-Squamous NSCLC
In combination with [pemetrexed] and platinum-containing chemotherapy, tislelizumab is indicated for the first-line treatment of adults with non-squamous NSCLC whose tumors:
- Have PD-L1 expression on ≥50% of tumor cells
- Have no EGFR or ALK-positive mutations and who have either: Locally advanced NSCLC not eligible for surgical resection or platinum-based chemoradiation, or Metastatic NSCLC.
[L49349]
Squamous NSCLC
In combination with [carboplatin] and either [paclitaxel] or nab-paclitaxel, tislelizumab is indicated for the first-line treatment of adults with squamous NSCLC who have either: Locally advanced NSCLC not eligible for surgical resection or platinum-based chemoradiation, or Metastatic NSCLC.
[L49349]
Also known as(7)
tirelizumab
Tirilizumab
Tislelizumab
Tislelizumab-jsgr
hPD-1
PD1
Protein PD-1
Drug interactions(417)
Known interactions with other medicines. Always consult a healthcare professional.
Darbepoetin alfa
Moderate
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tislelizumab.
Erythropoietin
Moderate
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tislelizumab.
Peginesatide
Moderate
The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tislelizumab.
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tislelizumab.
Diethylstilbestrol
Moderate
Diethylstilbestrol may increase the thrombogenic activities of Tislelizumab.
Chlorotrianisene
Moderate
Chlorotrianisene may increase the thrombogenic activities of Tislelizumab.
Conjugated estrogens
Moderate
Conjugated estrogens may increase the thrombogenic activities of Tislelizumab.
Estrone may increase the thrombogenic activities of Tislelizumab.
Estradiol may increase the thrombogenic activities of Tislelizumab.
Dienestrol
Moderate
Dienestrol may increase the thrombogenic activities of Tislelizumab.
Ethinylestradiol
Moderate
Ethinylestradiol may increase the thrombogenic activities of Tislelizumab.
Mestranol may increase the thrombogenic activities of Tislelizumab.
Estriol may increase the thrombogenic activities of Tislelizumab.
Estrone sulfate
Moderate
Estrone sulfate may increase the thrombogenic activities of Tislelizumab.
Quinestrol
Moderate
Quinestrol may increase the thrombogenic activities of Tislelizumab.
Hexestrol may increase the thrombogenic activities of Tislelizumab.
Tibolone may increase the thrombogenic activities of Tislelizumab.
Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Tislelizumab.
Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Tislelizumab.
Polyestradiol phosphate
Moderate
Polyestradiol phosphate may increase the thrombogenic activities of Tislelizumab.
Esterified estrogens
Moderate
Esterified estrogens may increase the thrombogenic activities of Tislelizumab.
Zeranol may increase the thrombogenic activities of Tislelizumab.
Equol may increase the thrombogenic activities of Tislelizumab.
Estetrol may increase the thrombogenic activities of Tislelizumab.
Promestriene
Moderate
Promestriene may increase the thrombogenic activities of Tislelizumab.
Methallenestril
Moderate
Methallenestril may increase the thrombogenic activities of Tislelizumab.
Epimestrol
Moderate
Epimestrol may increase the thrombogenic activities of Tislelizumab.
Moxestrol may increase the thrombogenic activities of Tislelizumab.
Estradiol acetate
Moderate
Estradiol acetate may increase the thrombogenic activities of Tislelizumab.
Estradiol benzoate
Moderate
Estradiol benzoate may increase the thrombogenic activities of Tislelizumab.
Estradiol cypionate
Moderate
Estradiol cypionate may increase the thrombogenic activities of Tislelizumab.
Estradiol valerate
Moderate
Estradiol valerate may increase the thrombogenic activities of Tislelizumab.
Biochanin A
Moderate
Biochanin A may increase the thrombogenic activities of Tislelizumab.
Formononetin
Moderate
Formononetin may increase the thrombogenic activities of Tislelizumab.
The risk or severity of adverse effects can be increased when Cetuximab is combined with Tislelizumab.
Human immunoglobulin G
Moderate
The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Tislelizumab.
Omalizumab
Moderate
The risk or severity of adverse effects can be increased when Omalizumab is combined with Tislelizumab.
Adalimumab
Moderate
The risk or severity of adverse effects can be increased when Adalimumab is combined with Tislelizumab.
The risk or severity of adverse effects can be increased when Abciximab is combined with Tislelizumab.
Gemtuzumab ozogamicin
Moderate
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Tislelizumab.
The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Tislelizumab.
Infliximab
Moderate
The risk or severity of adverse effects can be increased when Infliximab is combined with Tislelizumab.
Trastuzumab
Moderate
The risk or severity of adverse effects can be increased when Trastuzumab is combined with Tislelizumab.
The risk or severity of adverse effects can be increased when Rituximab is combined with Tislelizumab.
Basiliximab
Moderate
The risk or severity of adverse effects can be increased when Basiliximab is combined with Tislelizumab.
The risk or severity of adverse effects can be increased when Muromonab is combined with Tislelizumab.
The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Tislelizumab.
Ibritumomab tiuxetan
Moderate
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Tislelizumab.
Tositumomab
Moderate
The risk or severity of adverse effects can be increased when Tositumomab is combined with Tislelizumab.
Alemtuzumab
Moderate
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Tislelizumab.
Showing 50 of 417 interactions
Toxicity & overdose
There are no available data on the use of tislelizumab in pregnant women. Based on its mechanism of action, tislelizumab can cause fetal harm when administered to a pregnant woman.
[L49349]
Animal reproduction studies have not been conducted with tislelizumab. However, in murine models of pregnancy, blockade of PD-1/PD-L1 signaling has been shown to disrupt tolerance to the fetus and result in increased fetal loss.
[L49349]
Human IgG4 (immunoglobulins) are known to cross the placental barrier.
Therefore, tislelizumab, being an IgG4 variant, has the potential to be transmitted from the mother to the developing fetus.
[L49349]
Women should be advised of the potential risk to a fetus. Tislelizumab should not be used during pregnancy unless the clinical condition of the woman requires treatment with tislelizumab.
[L49349]
No clinical data are available on the possible effects of tislelizumab on fertility. No reproductive and development toxicity studies have been conducted with tislelizumab.
Based on a 3-month repeat-dose toxicity study, there were no notable effects in the male and female reproductive organs in cynomolgus monkeys when tislelizumab was given at doses of 3, 10, or 30 mg/kg every 2 weeks for 13 weeks (7 dose administrations).
[L49349]
There is no information on overdose with tislelizumab. In case of overdose, patients should be closely monitored for signs or symptoms of adverse drug reactions, and appropriate symptomatic treatment should be instituted immediately.
[L49349]
[L49349]
Animal reproduction studies have not been conducted with tislelizumab. However, in murine models of pregnancy, blockade of PD-1/PD-L1 signaling has been shown to disrupt tolerance to the fetus and result in increased fetal loss.
[L49349]
Human IgG4 (immunoglobulins) are known to cross the placental barrier.
Therefore, tislelizumab, being an IgG4 variant, has the potential to be transmitted from the mother to the developing fetus.
[L49349]
Women should be advised of the potential risk to a fetus. Tislelizumab should not be used during pregnancy unless the clinical condition of the woman requires treatment with tislelizumab.
[L49349]
No clinical data are available on the possible effects of tislelizumab on fertility. No reproductive and development toxicity studies have been conducted with tislelizumab.
Based on a 3-month repeat-dose toxicity study, there were no notable effects in the male and female reproductive organs in cynomolgus monkeys when tislelizumab was given at doses of 3, 10, or 30 mg/kg every 2 weeks for 13 weeks (7 dose administrations).
[L49349]
There is no information on overdose with tislelizumab. In case of overdose, patients should be closely monitored for signs or symptoms of adverse drug reactions, and appropriate symptomatic treatment should be instituted immediately.
[L49349]
How it works
Mechanism of action
Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumors.[L50341]
Tislelizumab is a humanized immunoglobulin G4 (IgG4) variant monoclonal antibody against PD-1, binding to the extracellular domain of human PD-1. It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signalling and enhancing the functional activity in T cells in in vitro cell-based assays.[L49349]
Tislelizumab is a humanized immunoglobulin G4 (IgG4) variant monoclonal antibody against PD-1, binding to the extracellular domain of human PD-1. It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signalling and enhancing the functional activity in T cells in in vitro cell-based assays.[L49349]
Pharmacodynamics
Tislelizumab decreased tumour growth in xenograft models and a human PD-1 transgenic mouse model.[L50341]
Pharmacokinetics
How the body processes this drug — absorption, distribution, metabolism, and elimination
Absorption
The pharmacokinetics (PK) of tislelizumab were characterized using population PK analysis with concentration data from 2 596 patients with advanced malignancies who received tislelizumab doses of 0.5 to 10 mg/kg every 2 weeks, 2.0 and 5.0 mg/kg every 3 weeks, and 200 mg every 3 weeks.
[L49349]
The time to reach 90% steady-state level is approximately 84 days (12 weeks) after 200 mg doses once every 3 weeks, and the steady-state accumulation ratio of tislelizumab PK exposure is approximately 2-fold.
[L49349]
Tislelizumab is administered intravenously and therefore is immediately and completely bioavailable.
[L49349]
[L49349]
The time to reach 90% steady-state level is approximately 84 days (12 weeks) after 200 mg doses once every 3 weeks, and the steady-state accumulation ratio of tislelizumab PK exposure is approximately 2-fold.
[L49349]
Tislelizumab is administered intravenously and therefore is immediately and completely bioavailable.
[L49349]
Half-life
Based on population PK analysis, the geometrical mean terminal half-life of tislelizumab was approximately 23.8 days with a coefficient variation (CV) of 31%.
[L49349]
[L49349]
Protein binding
Little information is available on the protein binding of tislelizumab.
Volume of distribution
A population pharmacokinetic analysis indicates that the steady-state volume of distribution is 6.42 L, which is typical of monoclonal antibodies with limited distribution.
[L49349]
[L49349]
Metabolism
Tislelizumab is expected to be degraded into small peptides and amino acids via catabolic pathways.
[L49349]
[L49349]
Clearance
Based on population PK analysis, the clearance of tislelizumab was 0.153 l/day with an interindividual variability of 26.3%.
[L49349]
[L49349]
Drug targets(1)
Proteins and enzymes this drug interacts with in the body
Programmed cell death protein 1
PDCD1
inhibitor
antibody
Specific functionsignaling receptor activity
Cellular location
Cell membrane
General function & pharmacology
Inhibitory receptor on antigen activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self .
PMID:21276005 PMID:37208329
Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 .
PMID:21276005
Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity)
PMID:21276005 PMID:37208329
Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2 .
PMID:21276005
Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). Suppresses T-cell activation through the recruitment of PTPN11/SHP-2: following ligand-binding, PDCD1 is phosphorylated within the ITSM motif, leading to the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2 that mediates dephosphorylation of key TCR proximal signaling molecules, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta (By similarity)
Scientific references(3)
Shen L., Kato K., Kim S.B., Ajani J.A., Zhao K., He Z., Yu X., Shu Y., Luo Q., Wang J., Chen Z., Niu Z., Zhang L., Yi T., Sun J.M., Chen J., Yu G., Lin C.Y., Hara H., Bi Q., Satoh T., Pazo-Cid R., Arkenau H.T., Borg C., Lordick F., Li L., Ding N., Tao A., Shi J., Van Cutsem E.
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Journal of Clinical Oncology
2022 Sep 1040(26):3065-3076. doi: 10.1200/JCO.21.01926. Epub 2022 Apr 20
Zhang T., Song X., Xu L., Ma J., Zhang Y., Gong W., Zhang Y., Zhou X., Wang Z., Wang Y., Shi Y., Bai H., Liu N., Yang X., Cui X., Cao Y., Liu Q., Song J., Li Y., Tang Z., Guo M., Wang L., Li K.
The binding of an anti-PD-1 antibody to FcgammaRIota has a profound impact on its biological functions.
Cancer Immunology Immunother
2018 Jul67(7):1079-1090. doi: 10.1007/s00262-018-2160-x. Epub 2018 Apr 23
Desai J., Deva S., Lee J.S., Lin C.C., Yen C.J., Chao Y., Keam B., Jameson M., Hou M.M., Kang Y.K., Markman B., Lu C.H., Rau K.M., Lee K.H., Horvath L., Friedlander M., Hill A., Sandhu S., Barlow P., Wu C.Y., Zhang Y., Liang L., Wu J., Paton V., Millward M.
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Journal Immunother Cancer
2020 Jun8(1):e000453. doi: 10.1136/jitc-2019-000453
ATC classification(1 code)
ATC L01FF09
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Tislelizumab
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72
Source: go.drugbank.comCC BY-NC 4.0
Updated 4 Mar 2026Structured knowledge from the free knowledge base
drugbank match (98%)
Linked open data from Wikidata (Q28209583), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.